Redhill Biopharma (Redhill Biopharma) EBIT per Share : $17.15 (TTM As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma EBIT per Share?

Redhill Biopharma's EBIT per Share for the three months ended in Jun. 2023 was $0.69. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $17.15.

During the past 3 years, the average EBIT per Share Growth Rate was 58.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 35.60% per year. During the past 10 years, the average EBIT per Share Growth Rate was 14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Redhill Biopharma's EBIT per Share or its related term are showing as below:

RDHL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -73.5 Med: 4.8 Max: 58.9
Current: 58.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Redhill Biopharma was 58.90% per year. The lowest was -73.50% per year. And the median was 4.80% per year.

RDHL's 3-Year EBIT Growth Rate is ranked better than
91.76% of 850 companies
in the Drug Manufacturers industry
Industry Median: 7.95 vs RDHL: 58.90

Redhill Biopharma's EBIT for the three months ended in Jun. 2023 was $2.69 Mil.

Redhill Biopharma EBIT per Share Historical Data

The historical data trend for Redhill Biopharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma EBIT per Share Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-56.49

-69.95

-69.80

-19.69

3.75

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-2.46	-1.26	20.17	0.69	-

Redhill Biopharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Redhill Biopharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	24.319	/	6.478
=	3.75

Redhill Biopharma's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	2.687	/	3.878
=	0.69

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.15

Redhill Biopharma (NAS:RDHL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Redhill Biopharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.